Recentin, for non-small cell lung cancer and colon cancer, will go to the FDA in 2009 or later.

FORBES: Cancer Drugs A Key In MedImmune Purchase

These drugs--such as Herceptin for breast cancer (Genentech) and Erbitux for colon cancer (Eli Lilly)--were designed to bind to signaling molecules on tumors and disrupt cell growth signals.

FORBES: Magazine Article